Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Randomized, Active-controlled, Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Intravenous BV100 Combined With Polymyxin B Versus Best Available Therapy in Adult Patients With Ventilator-associated Bacterial Pneumonia Suspected or Confirmed to be Due to Carbapenem-resistant Acinetobacter Baumannii

Next Previous
Trial Profile

A Multicenter, Open-label, Randomized, Active-controlled, Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Intravenous BV100 Combined With Polymyxin B Versus Best Available Therapy in Adult Patients With Ventilator-associated Bacterial Pneumonia Suspected or Confirmed to be Due to Carbapenem-resistant Acinetobacter Baumannii

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rifabutin (Primary) ; Polymixin B
  • Indications Ventilator associated pneumonia
  • Focus Pharmacokinetics
  • Sponsors BioVersys

Most Recent Events

  • 06 Nov 2025 According to a BioVersys AG media release, data from this study were presented at the 2025 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Vienna, Austria.
  • 28 Apr 2025 According to a BioVersys AG media release, Company will Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter on May 7, 2025.
  • 08 Apr 2025 According to a BioVersys AG media release, latest data from this trial will be presented at the 35th Congress of the European Society of Clinical Microbiology & Infectious Diseases (ESCMID Global 2025, April 11-15, 2025).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top